Written exposure therapy for post-traumatic stress disorder in residential treatment for substance use disorders: A randomized feasibility trial.

Addict BehavMay 5, 2026 (epub)
Clinical ResearchPsychiatry

Rebecca L Schacht, Kevin R Wenzel, Laurel E Meyer et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the feasibility of Written Exposure Therapy (WET) combined with treatment as usual (TAU) for PTSD in 42 participants undergoing residential treatment for substance use disorders. Results indicated that participants receiving TAU+WET experienced significantly greater reductions in PTSD symptoms compared to those receiving TAU alone, with 52% achieving PTSD remission versus 21% in the TAU group.

Key findings

  • Participants in the TAU+WET group showed a mean PTSD symptom reduction of -24.67 compared to -15.43 in the TAU group.
  • 52% of TAU+WET participants achieved PTSD remission compared to 21% in the TAU group.
  • TAU+WET participants demonstrated significantly greater improvements across all exploratory outcomes.

Why it matters

The co-occurrence of PTSD and substance use disorders complicates treatment, and integrating effective PTSD therapies like WET into residential care may improve patient outcomes and enhance overall treatment efficacy.

Source

Published in Addict Behav. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.